环球合伙公司

最新新闻

• 评级变动
  TR | OpenAI - 4o Maintains Global Partners(GLP.US) With Hold Rating, Maintains Target Price $53
  \u5e02\u573a\u8d44\u8baf · 2025/8/11
• 评级变动
  Neutral Outlook on Magnum Ice Cream Co.: Soft Demand, Margin Pressure, and GLP-1 Risks Cap Near-Term Upside
  TipRanks · 2026/2/12
• 公司公告
  ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES INU.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, ANDASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OFASC36 AND GLP-1R/G
  HKEX · 2026/8/10
• 公司公告
  ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS SUBMITS TWO IND APPLICATIONS TO THE U.S. FDAFOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, A PEPTIDE AMYLIN RECEPTOR AGONIST,AND ASC36_35 FDC ONCE-MONTHLY INJECTION,A CO-FORMULATION OF ASC36 PLUS PEPTIDE GLP-1R
  HKEX · 2026/7/6
• 公司公告
  ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE II STUDY OFASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST, FOR THETREATMENT OF DIABETES
  HKEX · 2026/4/27
• Will GLP-1s Hurt Food Stocks? Assessing the Changing Consumer.
  Yahoo Finance · 2026/9/24
• From AI Infrastructure to GLP-1 Drugs, Here Are Investment Pros' Favorite Niche ETFs Now -- Barrons.com
  Barron's · 2026/10/1
• Eli Lilly Scores FDA Win for Pancreatic Cancer Drug. How It's Moving Beyond GLP-1s. -- Barrons.com
  Barron's · 2026/10/6
• 评级变动
  Stifel Maintains Global Partners(GLP.US) With Hold Rating, Cuts Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2025/11/11
• Accelerating global expansion! Hengrui Pharma licenses its oral GLP-1/GIP weight-loss drug to Novo-Nordisk A/S, with potential deal value reaching up to $2.6 billion.
  wallstreetcn · 2026/9/29
• 公司公告
  ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR PHASE I STUDYOF ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, ASC35, FOR THE TREATMENT OF OBESITY
  HKEX · 2026/6/23
• 评级变动
  Raymond James Initiates Global Partners(GLP.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• Hengrui Pharma Seals Up to US$2.6 Billion Global Licensing Deal With Novo Nordisk for Oral GLP-1/GIP Drug
  TipRanks · 2026/9/29
• 公司公告
  Jiaze Renewables Corporation: Jiaze New Energy Co., Ltd. Simplified Equity Change Report (Information Discloser: GLP Renewable Energy Investment I Limited)
  SZSI · 2026/4/15
• 评级变动
  Morgan Stanley: Hims' Target Price is $40 with an 18% downside potential, and the GLP-1 lawsuit tug-of-war is the biggest variable.
  Zhitong Finance · 2025/7/9
• 评级变动
  TR | OpenAI - 4o Downgrades Global Partners(GLP.US) to Hold Rating, Cuts Target Price to $57
  \u5e02\u573a\u8d44\u8baf · 2025/8/6
• 评级变动
  Yinuos (688710): Nantong Yinuos' "High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform Expansion Project" has obtained NMPA GLP certification.
  Northeast Securities · 2026/6/11
• 评级变动
  CLSA: Upgrades Fosun Pharma (02196) target price to HKD 31.6 following GLP-1 drug collaboration with Pfizer (PFE.US).
  Zhitong Finance · 2025/12/10
• 评级变动
  Stifel Maintains Global Partners(GLP.US) With Hold Rating, Maintains Target Price $53
  \u5e02\u573a\u8d44\u8baf · 2025/8/13
• 评级变动
  GLP-1 drugs reshape consumer habits, and Wall Street rarely lowers McDonald's rating.
  wallstreetcn · 2025/6/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。